Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.
Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. Matsuzawa R, et al. Among authors: zenke y. EClinicalMedicine. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38034077 Free PMC article.
Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y, Matsumoto S, Zenke Y, Yoh K, Ikeda T, Shibata Y, Kato T, Nishino K, Nakamura A, Furuya N, Miyamoto S, Kuyama S, Nomura S, Ikeno T, Udagawa H, Sugiyama E, Nosaki K, Izumi H, Sakai T, Hashimoto N, Goto K. Tamiya Y, et al. Among authors: zenke y. Lung Cancer. 2023 Feb;176:103-111. doi: 10.1016/j.lungcan.2022.12.019. Epub 2022 Dec 31. Lung Cancer. 2023. PMID: 36634571
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka Y, Nakai T, Suzuki A, Kagawa Y, Noritake O, Taki T, Hashimoto H, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanbe R, Tsuboi M, Goto K, Ishii G. Tanaka Y, et al. Among authors: zenke y. Cancer Immunol Immunother. 2023 Jul;72(7):2205-2215. doi: 10.1007/s00262-023-03393-8. Epub 2023 Mar 2. Cancer Immunol Immunother. 2023. PMID: 36862151 Free PMC article. Review.
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Sakai T, Matsumoto S, Ueda Y, Shibata Y, Ikeda T, Nakamura A, Kodani M, Ohashi K, Furuya N, Izumi H, Nosaki K, Umemura S, Zenke Y, Udagawa H, Sugiyama E, Yoh K, Goto K. Sakai T, et al. Among authors: zenke y. J Thorac Oncol. 2023 Nov;18(11):1538-1549. doi: 10.1016/j.jtho.2023.07.024. Epub 2023 Aug 4. J Thorac Oncol. 2023. PMID: 37543207 Free article.
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G. Kitagawa S, et al. Among authors: zenke y. Lung Cancer. 2024 Feb;188:107453. doi: 10.1016/j.lungcan.2023.107453. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160515
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, Tanizaki J, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K. Asao T, et al. Among authors: zenke y. Clin Lung Cancer. 2023 Nov;24(7):e247-e253. doi: 10.1016/j.cllc.2023.05.004. Epub 2023 May 19. Clin Lung Cancer. 2023. PMID: 37316381 Clinical Trial.
Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer.
Ito H, Suzuki K, Mizutani T, Aokage K, Wakabayashi M, Fukuda H, Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group. Ito H, et al. J Thorac Cardiovasc Surg. 2020 Jan 11:S0022-5223(20)30054-4. doi: 10.1016/j.jtcvs.2019.12.072. Online ahead of print. J Thorac Cardiovasc Surg. 2020. PMID: 32067786 Free article.
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Fujiwara Y, et al. Among authors: zenke y. Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14. Cancer Sci. 2023. PMID: 36704833 Free PMC article.
110 results